High intensity focused ultrasound for locally recurrent prostate cancer following external beam radiation therapy investigated in Phase III clinical study | Ultrasound
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Ultrasound High intensity focused ultrasound for locally recurrent prostate cancer following external beam radiation therapy investigated in Phase III clinical study

High intensity focused ultrasound for locally recurrent prostate cancer following external beam radiation therapy investigated in Phase III clinical study

Radiology News
In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

In a new study, men with locally recurrent prostate cancer may be able to receive a promising investigational ultrasound treatment option.

A Phase III clinical trial at Specialists in Urology, located in North Naples, FL, is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT). HIFU is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves.

The lead investigator of this trial site is Dr. Nicholas Franco. This is one of several trial sites in the nation approved by the Food and Drug Administration to participate in the trial, which will begin enrolling patients in September.

HIFU is intended to eliminate cancer by elevating tissue temperatures to more than 195 degrees Fahrenheit in a matter of seconds. The Sonablate(R) 500, the therapeutic ultrasound device, which will be used in the study, is designed to destroy the entire gland in one procedure without causing damage to tissue around the prostate.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following EBRT, confined prostate cancer with a prostate specific antigen (PSA) greater than or equal to .5 ng/mL and less than or equal to 10 ng/mL and a Gleason score of less than or equal to seven.

 

Related Articles